Business Wire

NY-WELLA-COMPANY

1.12.2022 15:13:38 CET | Business Wire | Press release

Share
Successful Product Innovations and Portfolio Acquisition Drive Wella Company to Exceed Profit and Growth Expectations in Successful Second Year

Wella Company, a global leader in the $100 billion hair and nail segment of the beauty industry, is marking a successful second year as a standalone company, delivering year-over-year double-digit profit and growth ahead of expectations. In Fiscal Year 22, which closed at the end of June, Wella Company beat all targets on financial performance across the globe. Since its founding in December 2020, Wella Company has delivered continuous double-digit profit and growth ahead of expectations and is one of the fastest-growing beauty companies in the sector.

Wella Company’s portfolio includes iconic professional and retail hair, nail, and beauty tech brands Wella Professionals, O·P·I, ghd, Briogeo, Nioxin, Sebastian Professional, and Clairol.

“Our first two years of business have shown the enduring potential of the Wella Company portfolio – we are re-establishing category excellence in both hair and nails, and both professionals and consumers are falling in love again with our beautiful brands,” said Annie Young-Scrivner, CEO of Wella Company. “Our continued strong financial performance, coupled with growth and gain in market share across all categories, even in the challenging global context, is proof that our business is just beginning to tap into its full potential.”

Product Portfolio Expansion and Successes

Wella Professionals continues to lead the company’s overall portfolio growth, with double-digit performance, retaining its #1 share in Professional Color globally. The launch of Shinefinity, a professional glazing service and a new category entry for Wella Company, was the company’s strongest color launch ever, delivering +4% above target. Momentum is building behind the Care portfolio, led by Wella Care, Sebastian and Nioxin, all generating double-digit growth. Sebastian Professional is Wella Company’s second-largest pro brand and achieved double-digit growth this year with gains across all key markets, driven by the brand’s unique care/styling hybrid products such as Dark Oil and No Breaker. Nioxin continued to deliver strong performance with Net Revenue growing double-digit year-on-year in key regions like NA and EMEA. The company’s Retail Hair segment grew Net Revenue nearly +3% in FY22 while gaining share across most key markets.

The Briogeo acquisition (closed June 2022) further solidified the company’s eco-ethical haircare portfolio by adding the clean and green, natural hair care business, one of the fastest-growing brands today. Briogeo sells one of its award-winning Don't Despair, Repair! Deep Conditioning Masks every minute.

London-based ghd (good hair day) is redefining beauty tech and continues to dominate with its digital-centric strategy. The brand has delivered on average a double-digit annual growth rate over the last 4 years.

O·P·I is the #1 professional nail brand worldwide and #3 in US retail. In the US, the brand has seen 10 months of consecutive share gain in the Food, Drug, Mass (FDM) channel. Nature Strong, the brand’s first plant-based, natural origin nail lacquer, was the #1 Color Cosmetics Launch in all FDM this spring.

Expansion in eCommerce and Digital

Wella Company continues to propel growth by expanding its digital footprint and accelerating eCommerce. Its WellaStore B2B eCommerce platform continues to acquire customers globally, helping salon pros meet business needs from express ordering to planning their bookings to accessing training. In FY22, WellaStore grew its sales volume +30% and grew its customer base by +10%. In its consumer eCommerce channels, the company grew nearly 2.5x faster than the overall hair market, especially in EMEA and APAC.

Commitment to ESG

As the company continues to grow, it is furthering its commitment to sustainability and social impact via its three pillars: People, Planet and Products. In June 2022, Wella Company announced its environmental targets and its participation in the UN Global Compact, the world’s largest initiative for sustainability in business. In tandem with its second anniversary, Wella Company issued its ESG Manifesto, the first formal publication of its commitment to environmental, social and governance (ESG), as well as a new Code of Conduct, WE Care. The Company will issue its first formal ESG report in 2023.

About Wella Company

Wella Company is an innovative global leader in the beauty industry that combines 140+ years of earned wisdom and industry experience with the momentum of a newly minted independent entity. Now marking two years as a standalone company, Wella Company is one of the fastest-growing beauty companies in the sector. The company has a portfolio of iconic professional and retail hair, nail, and beauty tech brands including Wella Professionals, O·P·I, ghd, Briogeo, Nioxin, Sebastian Professional, and Clairol. The company serves legions of artists and owners across the professional hair and nail community in more than 100 countries. Each day, a diverse community of more than 91 million beauty lovers and industry professionals, social influencers, ambassadors, followers, employees, and customers engage with and are impacted by Wella Company products across the globe. With the belief that business can be a catalyst for positive change, Wella Company acts to enable people, organizations, and societies to collectively prosper. Environmental, Social, and Governance (ESG) is at the core of Wella Company’s purpose-led agenda. Sustainability and Diversity, Equity and Inclusion are fundamental to who we are, how we operate and how we support the industry and communities we serve. Wella Company is building the best beauty company in the industry, ensuring that when the industry thrives, we thrive. And as we make progress on our agenda to care for our planet and leave a positive impact on society, we will become a champion for change whose legacy will be worthy of our iconic history. For more information on Wella Company, visit www.wellacompany.com and follow us on LinkedIn and Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221201005715/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye